CAS: 2133-80-4 - 5-Amino-3,6-dihydro-3-β-D-ribofuranosyl-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one
Formula:C9H12N6O5
InChI:InChI=1S/C9H12N6O5/c10-9-11-6-3(7(19)12-9)13-14-15(6)8-5(18)4(17)2(1-16)20-8/h2,4-5,8,16-18H,1H2,(H3,10,11,12,19)/t2-,4-,5-,8-/m1/s1
InChI key:InChIKey=QOVIBFFZCVPCEI-UMMCILCDSA-N
SMILES:O=C1N=C(N)NC2=C1N=NN2C3OC(CO)C(O)C3O
- Synonyms:
- 3H-v-Triazolo[4,5-d]pyrimidin-7(6H)-one, 5-amino-3-β-D-ribofuranosyl-
- 7H-v-Triazolo[4,5-d]pyrimidin-7-one, 5-amino-3,6-dihydro-3-β-D-ribofuranosyl-
- 3H-v-Triazolo[4,5-d]pyrimidin-7-ol, 5-amino-3-β-D-ribofuranosyl-
- 7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one, 5-amino-3,4-dihydro-3-β-D-ribofuranosyl-
- 7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one, 5-amino-3,6-dihydro-3-β-D-ribofuranosyl-
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
8-Azaguanosine REF: TM-TNU0541CAS: 2133-80-4 | 99.44% | 182.00 €~1,710.00 € | Thu 12 Dec 24 | |
8-Azaguanosine REF: TR-A797310CAS: 2133-80-4 | - - - | 2,143.00 € | Tue 21 Jan 25 | |
8-Azaguanosine REF: 3D-CAA13380CAS: 2133-80-4 | Min. 95% | To inquire | Tue 21 Jan 25 |
8-Azaguanosine
CAS:2133-80-4
8-Azaguanosine is a purine nucleoside analog with a broad spectrum of antitumor activity and is …
Formula:
C9H12N6O5
Purity:
99.44%
Color and Shape:
Liquid
Molecular weight:
284.23
Ref: TM-TNU0541
1mg | 182.00 € | ||
5mg | 400.00 € | ||
10mg | 593.00 € | ||
25mg | 920.00 € | ||
50mg | 1,271.00 € | ||
100mg | 1,710.00 € |
Estimated delivery in United States, on Thursday 12 Dec 2024
8-Azaguanosine
Controlled ProductCAS:2133-80-4
Formula:
C9H12N6O5
Color and Shape:
Neat
Molecular weight:
312.37
Ref: TR-A797310
25mg | 2,143.00 € |
Estimated delivery in United States, on Tuesday 21 Jan 2025
8-Azaguanosine
CAS:2133-80-4
8-Azaguanosine is a potent inhibitor of kinases that has been shown to have anticancer properties. …
Formula:
C9H12N6O5
Purity:
Min. 95%
Molecular weight:
284.23 g/mol
Ref: 3D-CAA13380
5mg | To inquire | ||
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire |
Estimated delivery in United States, on Tuesday 21 Jan 2025